HOWL Stock Summary and Trading Ideas (Werewolf Therapeutics | NASDAQ:HOWL)

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

Werewolf Therapeutics trades on the NASDAQ stock market under the symbol HOWL.

As of February 12, 2026, HOWL stock price declined to $0.66 with 208,385 million shares trading.

HOWL has a beta of 2.55, meaning it tends to be more sensitive to market movements. HOWL has a correlation of 0.15 to the broad based SPY ETF.

HOWL has a market cap of $30.18 million. This is considered a Sub-Micro Cap stock.

Last quarter Werewolf Therapeutics reported $0 in Revenue and -$.36 earnings per share. This fell short of revenue expectation by $-600,000 and exceeded earnings estimates by $.03.

In the last 3 years, HOWL traded as high as $8.19 and as low as $.53.

The top ETF exchange traded funds that HOWL belongs to (by Net Assets): VTI, VXF.

HOWL has underperformed the market in the last year with a price return of -56.6% while the SPY ETF gained +14.1%. HOWL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -41.6% and -7.5%, respectively, while the SPY returned +0.4% and -1.7%, respectively.

HOWL support price is $.62 and resistance is $.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HOWL shares will trade within this expected range on the day.